Anika Therapeutics ANIK Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Net margin | -9.9%+36.6pp | -46.5%+3.1pp | -49.6%-40.1pp | -9.5%— | |
| Free cash flow margin | 3.9%— | —— | —— | —— | |
| Returns | |||||
| Return on equity | -7.5%+23.3pp | -30.8%+2.4pp | -33.2%-28.0pp | -5.2%— | |
| Return on assets | -5.7%+18.1pp | -23.8%+2.9pp | -26.7%-22.4pp | -4.3%— | |
| Efficiency | |||||
| Asset turnover | 0.6×+0.1× | 0.5×0.0× | 0.5×+0.1× | 0.4×0.0× | |
| Liquidity | |||||
| Current ratio | 4.7×-0.2× | 4.9×-0.4× | 5.3×-0.8× | 6.1×+0.4× | |
| Quick ratio | 3.9×0.0× | 3.9×-0.6× | 4.5×-0.2× | 4.6×+0.2× | |
| Cash ratio | 2.6×+0.2× | 2.4×+0.2× | 2.2×-0.9× | 3.1×-0.1× | |
| Leverage | |||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Valuation | |||||
| Market capitalization | $204.37M+31.6% | $241.07M-27.3% | $331.76M-23.3% | $432.45M-16.4% | |
| Enterprise value | $189.09M+48.7% | $211.37M-27.3% | $290.76M-22.4% | $374.94M-15.2% | |
| Price / sales | 1.8×+0.1× | 2×0.0× | 2×-0.8× | 2.8×-0.7× | |
| Price / book | 1.5×+0.5× | 1.6×0.0× | 1.6×0.0× | 1.5×-0.3× | |
| EV / sales | 1.6×+0.3× | 1.7×0.0× | 1.7×-0.7× | 2.4×-0.6× | |
| Free cash flow yield | 0.5%— | —— | —— | —— | |
| Earnings yield | -5.6%+33.5pp | -23.4%+1.5pp | -24.9%-21.5pp | -3.4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Anika Therapeutics's ratios come from?
- Every ratio is computed from Anika Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
